Competing with 50 teams from around the world in the Prostate Cancer DREAM Challenge, University of Alberta’s PC LEARN team tied for 1st in one of the 3 sub-challenges
to predict the survival and toxicity of Docetaxel treatment in patients with metastatic castrate resistant prostate cancer!
“The DREAM Challenge was an exciting opportunity for us to apply machine learning to real medical data and possibly to contribute to medical research.” said lead PI and APCaRI member Russ Greiner.
The primary benefit of this Challenge will be to establish new quantitative benchmarks for prognostic modeling in mCRPC, with a potential impact for clinical decision making and ultimately understanding the mechanism of disease progression. https://www.synapse.org/#!Synapse:syn2813558/wiki/70844